<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the safety and efficacy of combined treatment with rituximab plus CHOP in 16 patients with relapsed advanced-stage follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The intent-to-treat overall response rate (ORR) was 88%, 75% complete remissions (CR) and 13% partial remissions (PR) </plain></SENT>
<SENT sid="2" pm="."><plain>At a median follow-up of 18 months, 63% of the patients are alive (50% CR) </plain></SENT>
<SENT sid="3" pm="."><plain>The combination of rituximab and CHOP in relapsed advanced-stage follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> achieves high ORRs and CRs, with low toxicity except for in previously autografted patients </plain></SENT>
</text></document>